An Extension Study to Evaluate the Long-Term Safety of Lampalizumab in Participants With Geographic Atrophy

Summary

This is a multicenter, open-label extension study of safety and tolerability of lampalizumab administered by intravitreal (ITV) injection to participants with geographic atrophy (GA) who have completed the 18-month treatment in Study CFD4870g (GX01456) (NCT01229215) or 24-week treatment in Study GX29455 (NCT02288559).

Timeline

Start

2012-05-29

Primary completion

2017-11-08

Completion

2018-02-09

Outcome

Outcome not reported

Stopped: “The study was terminated early by the Sponsor due to lack of efficacy.”

Drugs

Indications